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Abstract. Epigenetics is emerging as the missing link among genetic inheritance, environmental influences, and body and
brain health status. In the brain, specific changes in nucleic acids or their associated proteins in neurons and glial cells might
imprint differential patterns of gene activation that will favor either cognitive enhancement or cognitive loss for more than
one generation. Furthermore, derangement of age-related epigenetic signaling is appearing as a significant risk factor for
illnesses of aging, including neurodegeneration and Alzheimer’s disease (AD). In addition, better knowledge of epigenetic
mechanisms might provide hints and clues in the triggering and progression of AD. Intense research in experimental models
suggests that molecular interventions for modulating epigenetic mechanisms might have therapeutic applications to promote
cognitive maintenance through an advanced age. The SAMP8 mouse is a senescence model with AD traits in which the study
of epigenetic alterations may unveil epigenetic therapies against the AD.
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INTRODUCTION
Today we are immersed in one of the most impor-
tant processes that have occurred throughout the
history of humanity: our world is getting old. Due
to the increase in life expectancy, we have a large
number of people over 60 years of age, up from 900
million in 2017, to nearly 2 billion in 2050 [1]. This
fact would be a success in itself, but at the same time,
diseases associated with aging have increased. In fact,
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aging has been established as the main risk factor for
all types of dementia, such as Alzheimer’s disease
(AD). Thus, it is a challenge to understand the mech-
anisms that intervene in aging and neurodegeneration
in order to prevent and/or treat chronic neurological
diseases associated with the age.
The role of epigenetics in the control of tran-
scriptional mechanisms comprises one of the earliest
emerging fields in senescent processes. These
aging-associated transcriptional signatures appear
to be controlled by reciprocal regulation among
chromatin-modifying enzymes, epigenetic marks,
and microRNAs (miRNAs) [2].
In the last 17 years, epigenetics has been revealed
as a crucial mechanism in the functioning of the
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nervous system and it participates in neuropsychiatric
diseases as well as in cognition, learning, and mem-
ory formation [3]. Many neurological diseases are
related to alterations in the epigenetic machinery, and
more and more indications suggest their importance
in many others. AD is no exception, and early studies
are beginning to identify epigenetic alterations in this
neurodegenerative pathology [4].
Senescence Accelerated Prone Mouse 8 (SAMP8)
is a feasible model to study aging processes and,
specifically, cognitive impairment and the molecu-
lar hallmarks of AD. Increasing evidence is found
in the SAMP8 brain that links epigenetic changes
with accelerated aging processes in this mouse strain.
Consequently, we will present how epigenetic mech-
anisms interact and cooperate in the regulation of
several targets that take part in senescence, cognitive
decline, and AD-like pathobiology in SAMP8.
BRAIN AGING AND ALZHEIMER’S
DISEASE
Neurodegeneration in aging
Aging induces a slow decrease in cerebral func-
tion, which leads to cognitive impairment, memory
loss, motor disorders, and finally, can reach func-
tional decay and death. Among the main features of
aging, we might find genomic instability, telomere
shortening, epigenetic alterations, loss of proteosta-
sis, nutrient detection deregulation, mitochondrial
dysfunction, cellular senescence, stem-cell deple-
tion, and altered intercellular communication [5, 6].
The brain is a high energy-consumption organ that
requires about 20% of the body’s total basal oxygen
to function [7]. Therefore, alterations in the cere-
bral energy metabolism lead to disease, from subtle
modifications in neuronal function to cellular death
and neurodegeneration [8]. As aging progresses, the
brain is susceptible to its intrinsic and extrinsic cell
signaling and to the systemic environment. Stud-
ies performed on the brains of elderly subjects not
previously diagnosed with a neurological disease
have shown the presence of extracellular amyloid-
 (A) and neurofibrillary tangles (NFTs), among
other pathological alterations. These features might
vary from individual to individual; the cause is not
known or whether they could be the precursors of neu-
rodegeneration. Some of them are probably the result
of general aging processes. Alternatively, others
might indicate a preclinical stage before AD clinical
symptoms appear, which might last for decades
[9]. In any case, the causes have not been identi-
fied that trigger the switch from normal aging to
neurodegeneration and AD. Aging is a process regu-
lated by different molecular and genetic mechanisms.
There are four molecular longevity pathways known:
decrease of insulin signaling; the increase of AMPK
(AMP-activated Protein Kinase); the diminishing of
TOR (Target of Rapamycin); and sirtuins.
In general, each cell possesses defense mecha-
nisms to cope with oxidative stress (OS). These
antioxidant defenses are endogenous enzymes and
include superoxide dismutase (SOD), glutathione
peroxidase, catalase, glutathione, thioredoxin reduc-
tase, and peroxiredoxins. Along with the aging
process, several factors, such as a naturally decreased
capacity of the antioxidant enzyme system, create
an imbalance between antioxidant mechanisms and
reactive oxygen system (ROS)-production equilib-
rium, accumulating ROS beyond the detoxifying
capacity of the antioxidant system resulting in OS,
eventually causing cellular damage that can no longer
be repaired by internal mechanisms, finally leading
to dysfunction of the system [10].
As previously mentioned, aging and neurodegen-
eration are closely related. The increase in OS,
mitochondrial dysfunction, and the inflammatory
response have been linked to accelerated aging
and the progression of neurodegenerative diseases
[10, 11]. ROS and reactive nitrogen species are the
main molecules contributing to OS. The most stud-
ied free radicals are superoxide (O2−), hydrogen
peroxide (H2O2), hydroxyl (HO), nitric peroxide
(ONO2–), and the nitric oxide free radical (NO).
OS is the resulting redox state from disequilib-
rium between the generation and detoxification of
ROS. Overproduction of ROS by the dysfunctional
mitochondrion, in addition to the imbalance in
mitochondrial fission/fusion and mitochondrial DNA
mutations, can cause oxidative damage to the cells,
inducing alterations to their biochemical and physio-
logical functions and modify the genetic expression
profiles inducing apoptosis and, thereafter, neurode-
generative pathologies [7, 12, 13].
Accumulative damage by free radicals over a cer-
tain time leads to major brain inflammation. There-
fore, stress can also interfere with the homeostatic
balance between anti- and proinflammatory cytokines
and induce neurodegeneration. The cytokines are sig-
naling proteins secreted by the cell in response to,
predominantly, intra- and extraneuronal conditions.
Neuroinflammation is a physiological response of the
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brain to an injury, infection, or disease in order to pre-
vent a potential damage, neuronal destruction, or to
dispose of a damaging agent. Several cytokines are
small-secreted proteins released by both microglia
and astrocytes in the central nervous system (CNS)
during the inflammatory response. Stress can increase
the levels of proinflammatory cytokines, such as
tumor necrosis factor-alpha (TNF-), interleukin
1beta (IL)-1, and IL-6 and can decrease the expres-
sion of anti-inflammatory cytokines IL-10, IL-4, and
the transforming growth factor beta (TGF-), exert-
ing a harmful effect on neurogenesis, inducing cell
death, and causing neurodegeneration [6]. Microglia
activation is a key factor in AD progression and
leads to increasing the chronic inflammatory state of
the CNS during aging, caused by immune pathway
dysregulation. Therefore, it is important to maintain
control of microglial activation.
Another feature that has appeared as a central reg-
ulator of CNS aging is autophagy because it plays
a crucial role as a control degradation point by
which defective proteins, organelles, and other cellu-
lar constituents are sequestered in autophagosomes
and delivered to lysosomes for degradation. Many
of the detrimental modifications previously men-
tioned, such as proteostasis loss, nutrient detection
alterations, mitochondrial damage, cellular senes-
cence, and stem-cell depletion, could occur by means
of basal autophagy deterioration and/or decrease of
autophagic degradation activity during cellular stress,
aging and neurodegenerative disorders [14, 15].
Hallmarks of Alzheimer’s disease
AD is a progressive, devastating neurodegener-
ative disorder that leads to behavioral, cognitive,
and memory deficits, as well as motor alterations
[16]. AD patients suffer from language and learning
difficulties, judgment loss, anxiety, depression, and
irritability. AD etiology is still not clear, although
there are some risk factors, both genetic and environ-
mental. Neuropathological hallmarks of AD include
lesions such as the presence of intracellular neurofib-
rillary tangles and the accumulation of A plaques in
specific brain regions and cerebral amyloid angiopa-
thy, reactive gliosis, and neuroinflammation [16],
OS, calcium homeostasis disruption, neuronal and
synaptic loss, altered functional connectivity among
the brain areas, and, finally, neuronal loss and brain
atrophy [17].
AD is classified into two types, familial and spo-
radic, depending on the etiology and the age of
the patient when symptoms appeared. Familial AD
(FAD) is inherited in an autosomal-dominant pattern
with symptoms typically presented in the 4th or 5th
decade of life. On the other hand, sporadic late-onset
AD (LOAD) usually begins in the 7th-8th decade of
life and is the more common of the two. The main
risk factor for LOAD is aging [18, 19].
Increasing evidence suggests that AD pathogen-
esis is not restricted to the neuronal compartment,
but includes strong interactions with immunological
mechanisms in the brain [20]. However, it should be
borne in mind that the elderly also have higher levels
of inflammation. Therefore, in the literature, we often
find the term inflammaging, although not as much as
in AD patients.
Genome-wide association analysis suggests that
several genes that increase the risk for sporadic AD
encode factors that regulate glial clearance of mis-
folded proteins and the inflammatory reaction [20].
External factors, including systemic inflammation,
changes in intestinal microbiota composition, and
obesity, are likely to interfere with immunological
processes of the brain and further promote disease
progression [20–22]. Regarding FAD, the pathogenic
mutations of the APP, PSEN1, and PSEN2 genes
cause autosomal-dominant AD represented in less
than 0.1% of the total AD cases [23]. The over-
whelming majority of AD cases are sporadic and
of unknown etiology. Currently, it is accepted that
AD is a multifactorial disease; consequently, there is
a remarkable effect of environmental factors in the
etiology of AD [24]. Therefore, an adequate epige-
netic intervention, beginning early in life as well as an
elderly stage of life can identify and combat harmful
molecular mechanisms through activation of neuro-
protective gene expression such as the brain-derived
neurotrophic factor (Bdnf), Bcl2, and Bcl-XL, among
others, by environmental enrichment (EE) [25].
EPIGENETICS
Nowadays, more than twenty different epigenetic
mechanisms have been identified [26–29], consist-
ing mainly of processes that can directly modify the
DNA, as in the case of DNA methylation, or mod-
ifications in the structure of chromatin, such as the
modification of histones or alteration of the processes
related to mRNA, such as, for example, non-coding
RNA among which miRNAs were found.
The CNS is highly sensitive to environmental
factors; thus, epigenetic disturbances are associated
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with neurological diseases [3, 30]. The CNS has a
higher diversity of cell types with a highly specialized
structural organization, tightly regulated by the epi-
genetic mechanism in response to the environment. In
addition, expression patterns are being continuously
modulated by brain activity, memory, and learning
[31]. Alterations in the epigenetic information give
rise to deregulation of the expression, resulting in the
development of several pathologies, including AD.
Methylation of DNA
The only epigenetic mechanism that directly mod-
ifies mammalian DNA is methylation of the cytosine
carbon ring in the dinucleotides of the CpG islands
[32]. Most of the genome does not contain the dinu-
cleotide CpG repeats; however, it concentrates on the
so-called CpG islands, located in regulatory regions
5’ of the genes. It is estimated that about 70% of CpG
dinucleotides in the genome are methylated in nor-
mal somatic cells [33]. DNA methylation has been
considered a normal mechanism of gene silencing
with a crucial role in the transcriptional repres-
sion of repeated and centromeric regions. However,
the mechanism is an efficiently regulated dynamic
process in which methyl groups might be added
or removed from both DNA strands. The result of
both actions, methylation, and demethylation, is not
permanent, which means that the mechanism of reg-
ulation is much more complex. However, some DNA
methylation patterns are erased whereas others are
maintained in the germline contributing to alter genes
expression in a heritable manner without affecting the
underlying genomic sequences. It should be kept in
mind that most of the constitutive expression genes
and a part of the tissue-specific genes and regula-
tory genes contain CpG islands in their promoter
regions. While changes in DNA methylation occurs
naturally during development, for example, inactiva-
tion of the X chromosome in females or the genomic
imprint during development, where it is decided
which parental allele will be expressed in the embryo
[33], they also arise in response to external factors
and aging, and are part of the modifications of vari-
ous diseases such as fragile X syndrome, cancer, or
neurodegenerative diseases, among many others.
DNA methylation is catalyzed by different mem-
bers of the DNA MethylTransferase family (DNMTs)
to form 5’-methyl-cytosine [34]. In mammalian cells,
three different enzymes have been identified: DNA
MethylTransferase 1 (DNMT1) and two de novo
MethylTransferase (DNMT3A and DNMT3B). Dur-
ing the S phase, DNMT1 copies the methylation
patterns of the parent strand to the daughter strand
of DNA, so that methylation is inherited after cell
division [35]. DNMT1 interacts with protein com-
plexes involved in transcriptional repression, which
include Histone DeACetylases family (HDACs) [36].
DNMT3A and DNMT3B are able to introduce a
methyl group to unmethylated CpG dinucleotides
to give methylated CpG. In addition, there are two
more methyltransferases, DNMT2 and DNMT3L;
DNMT2 is different from all other DNMTs because
it methylates cytosine 38 in the anticodon loop of
aspartic acid transfer RNA, and DNMT3L differs
from other DNMTs because it lacks catalytic motif
and does not have methyltransferase activity but it
contributes to de novo methylation process interact-
ing with DNMT3A or DNMT3B [37–39]. Promoters
that have been silenced by methylation can be reacti-
vated, when demethylated. As for the mechanisms
responsible for demethylation, there are two: pas-
sive demethylation, the mechanism of which arises
by reduction or disappearance of DNMT1 function
during replication, and active demethylation: this
alternative mechanism is a catalytic removal of the
methyl groups carried out by Ten-Eleven Translo-
cation family (TETs) members of DNA hydroxylase
family that oxidize the base and the subsequent action
of the protein Thymine-DNA-Glycosylase, which
will split the oxidized base.
Hydroxymethylation of DNA
5-hydroxymethylCytosine (5-hmC) was initially
discovered in the 1950 s in bacteriophage and was
observed in mammals in the 1970 s. It is the first
oxidative product in the active demethylation of 5-
mC. 5-hmC has been referred to as the “sixth base”
because of its involvement in gene transcription in
a similar way to 5-mC [40]. It has been detected
that approximately 1% of cytosines in mammals are
hydroxymethylated, although the level of hydrox-
ymethylation varies depending on the tissue, with
nervous tissue exhibiting higher levels [41]. Stem
cells also have higher levels of 5-hmC decreas-
ing during differentiation [41, 42]. 5-hmC is an
intermediary of 5-mC demethylation. This mech-
anism has been demonstrated by the discoveries
of different intermediates 5-formylCytosine (5-fC)
and 5-carboxyCytosine (5-caC) in mouse genomic
DNA [43]. The hydroxymethylation of the DNA is
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catalyzed by three enzymes belonging to the TETs.
These comprise TET1, TET2, and TET3. This family
of enzymes carries out repeated oxidations of 5-hmC
into 5-fC generating 5-caC. In addition, TET1 and
TET2 have demonstrated to play an important role in
gene control and cell death in neurons [44], whereas
TET3 is related to early embryonic-development pro-
cesses [45]. Overall, hydroxymethylation of cytosine
in a promoter gene or in CpG islands have been asso-
ciated with an increase in gene transcription, i.e., it
has an opposite effect to that of methylation [46].
In addition, these could affect the activity of dif-
ferent Methyl-CpG-binding domain proteins, thus
modifying their recruitment during chromatin reg-
ulation or have direct effects on transcription. On
the other hand, differential gene expression of TET
enzymes was described at distinct stages of develop-
ment or tissue. Regarding TET1, we found that it is
expressed mainly in embryonic stem cells, whereas
TET2 and TET3 are more common in all other tissue
types [42].
Chromatin remodeling and histone modifications
Chromatin remodeling is a process that controls
the dynamic chromatin structure to allow access
of the genetic information encoded into the DNA.
Such remodeling is principally carried out by post-
translational modifications (PTMs), which it requires
the interactions between DNA methylation and his-
tone modifications to change the accessibility of the
transcriptional machinery. At least 16 histone mod-
ifications are known. As a result of a large number
of modifications that can be done, there is a great
potential for functional control of chromatin struc-
ture by histone modifications. However, an extra level
exists due to the combination of different modifica-
tions give rise to the so-called “code of histones”. This
cross-talk can occur via multiple mechanisms [47].
As a consequence, these modifications mediate a
variety of biological functions, including recruitment
of protein machinery that modulate transcription,
repair, and DNA replication. The “writers” are
enzymes, which add specific PTMs to histone sub-
strates making the chromatin in compacted or relaxed
conformation, and leads to transcriptional repres-
sion or activation, respectively, and are divided into
classes based on the specific PTM they affect. In
contrast, “erasers” are enzymes that remove spe-
cific PTMs from histone substrates restoring the
interaction between the histone and DNA, and are
divided into PTM-specific classes. Finally, “read-
ers” do not alter the histone and recognize either
post-translational marks or combination of marks and
histone variants. These proteins will act as effectors,
being responsible for the activation or repression of
transcription and chromatin packaging, among oth-
ers.
Therefore, a wide variety of modifications exist as a
consequence of the enzymatic activity of antagonistic
complexes, mainly including acetylation, methyla-
tion, phosphorylation, ubiquitination, sumoylation,
ADP-ribosylation, and adenylations. These tags par-
ticipate in the regulation either by altering the
interactions of DNA and histones or by generating
a recognition platform necessary to recruit to the
proteins readers with different activities.
Histone acetylation and deacetylation
Proteins with lysine acetyltransferase activity have
been identified and characterized with an important
role in gene regulation [48, 49]. These enzymes acety-
lated histone tails on the ε-amino of lysine residues.
Both proteins, the histone acetyl transferases (HATs)
and HDACs, do not bind directly to DNA but act on
it through a multicomplex that includes transcription
co-activators and co-primers [50, 51]. This process
leads to the activation of transcription by neutralizing
the positive charge of the lysine, causing a reduction
in the affinity of histones for DNA. The degree of
histone acetylation at specific genomic sites is the
net result of a balance between these enzymes.
The acetylation process is carried out by several
HATs (Table 1). In general, these form part of the
multi-component complexes, grouping in different
families:
HDACs catalyze the removal of the acetyl group
from -acetyl-lysine [52], decreasing the acety-
lation levels. Hypoacetylation increases chromatin
compaction leading to transcriptional repression
[53]. Modulation of the activity of HDACs
occurs through protein-protein, post-translational
modifications (sumoylation, phosphorylation, and
proteolysis), subcellular location/translocation, and
the availability of metabolic co-factors [54].
At least 18 HDACs genes have been identified in
the human genome [55]. All HDACs perform mul-
tiple cellular functions of great importance, and the
deregulation of HATs and HDACs are implicated in
the progression of several pathologies, including AD
and the senescence process. Among HDACs, sirtu-
ins are NAD+ dependent deacetylases that exhibit
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Table 1
HAT families and acetylated sites
HAT families Sites of Histone Modifications
GNAT/PCAF Gcn5, PCAF, ELP3 H3K9, H3K14, H3K18, H4K5, H4K8, H4K12, H4K16
MYST Tip60, MOZ, MORF, HBO1, HMOF H3K14, H4K5, H4K8, H4K12, H4K16
p300/CBP p300, CBP H2AK5, H2BK12, H2BK15, H3K14, H3K18, H4K5
Table 2
Histone methylation enzymes




methyltransferases containing the SET
domain (Su (var) 3–9, Enhancer of
Zeste, Trithorax)
Methylations in histones H3 (residues
K4, K9, K27, and K36) and H4 (K20).
Lysine methyl-transferases without SET
domain
Methylate to H3K79
Arginine methyltransferases Methylate- distinct arginine residues in
histones H3 and H4
Histones DeMethylases
(HDMs)
LSD demethylases function as
FAD-dependent amino acids (flavin
adenine dinucleotide)
JMJC demethylases function as
2-oxo-glutarate-FE (II)-dependent
dioxygenase
neuroprotective effects against cerebral age-related
disorders [56]. In mammals, there are seven sirtuins
homologs called SIRT1-7, with different locations
and enzymatic activities [57]. The most preserved
family member is SIRT1, a nuclear protein that has
been widely investigated in neurodegenerative dis-
eases [58].
Histone methylation
Histone methylation is an epigenetic marker that
is more stable than the acetylation of histones. This
takes place in the lysine and arginine side chains
of histones [59]. The enzymes responsible for the
methylation of specific residues are denominated
HMTs and can be grouped into three different fam-
ilies, as depicted in Table 2. These three families,
in turn, contain several subfamilies classified by the
methylation that they produce. Methylation of argi-
nine residues is common in eukaryote organisms.
Note that while arginine methylation is mainly related
to transcriptional activation, the same lysine modi-
fication might be associated with the activation and
repression of gene expression, depending on the mod-
ified site and the degree of methylation of each
residue.
Histone methylation is reversible and highly
dynamic, and homeostasis of methylation is main-
tained by the antagonistic activity of the writers and
erasers of methylation, which are responsible for
establishing and eliminating methylation markers,
respectively [60]. This process of histone demethy-
lation is carried out by the Histone DeMethylases
family (HDMs) (Table 2).
Other histone modifications
Other modifications of histones, such as phos-
phorylation, ubiquitination, sumoylation, ADP-
ribosylation, deiminiation, and proline isomerization,
intervene to a lesser extent in post-translational modi-
fications of histones, thereby regulating transcription
[61, 62].
Non-coding RNAs and microRNAs
Analysis of the transcriptome has revealed that,
although it depends on the species, only 1.5% of
the genome encodes RNA that culminate in protein
transcripts, resulting in a broad repertoire of tran-
scripts, more than 65%, of RNA that are not translated
into proteins and that are called non-coding RNA
(ncRNA). Non-coding RNA are classified depending
on their size, as (lncRNA, “Long non-coding RNA")
with more than 200 nts, and as (“Short non-coding
RNA”, sncRNA), of less than 200 nts. There are sev-
eral subtypes between sncARN and lncRNA, many of
which are involved in the regulation of gene expres-
sion and can be grouped according to the genomic
origin and biogenic processes [63, 64].
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MicroRNAs are small non-coding RNA molecules
between 18 and 25 nucleotides that are expressed in
the eukaryotic nucleus in both intra- and intergenic
regions and that are responsible for the repres-
sion of gene expression [65, 66]. miRNAs vary in
their mechanism of action depending on the degree
of complementarity with their target mRNA, as
follows: 1) inhibition of translation; 2) stopping
the elongation phase; 3) the premature arrest of
ribosomes; and 4) degradation of mRNA at the co-
transduction level.
There are 28,645 identified miRNAs precursors
expressing approximately 35,828 mature miRNAs in
223 species [66, 67]. It is estimated that between 30
and 90% of human genes might be regulated by miR-
NAs, and each miRNA can regulate up to 100 genes,
which could potentially regulate a large number of
protein-coding genes [68].
The first described miRNA was lin-4 in
Caenorhabditis elegans [69]. The relevance of this
study was its demonstration of the implication of
miRNAs in the development of C. elegans. Subse-
quently, several studies were carried out involving
miRNAs in programmed cell death in flies [70], in
early and late vertebrate development [71, 72], as
well as in certain physiological functions in humans,
such as adipocyte differentiation, antiviral defense,
neuronal development, or apoptosis [73], with a very
profound impact in cardiovascular diseases [65, 74],
diabetes [75], schizophrenia [76], and neurodegener-
ative diseases such as AD [73].
Interactions among epigenetic mechanisms
All of the machinery of histone-modifying
enzymes does not act independently, as has been
mentioned, but is associated with large multiprotein
complexes that, together, modify chromatin struc-
ture regulating gene transcription. In turn, miRNAs
regulate gene expression in which a profound inter-
action between different epigenetic modifications is
established. Thus, a strong relationship is observed
between the methylation of DNA and the modifica-
tions of the histones that, acting together, are able
to regulate the majority of the transcription pro-
cess along the whole genome. In addition, histone
modifications have been found to play a positive or
negative role in controlling the expression of miRNA
genes from both normal and pathological cells [77,
78]. On the other hand, miRNAs exert beneficial
effects on the regulation of DNA methylation or
histone modification through the direct regulation




Changes in the epigenome during aging lead to
alterations in gene regulation and genomic insta-
bility, mainly contributing to the appearance of
age-related diseases such as cancer and neurodegen-
erative diseases, among others [2]. As mentioned
earlier, aberrant gene expression, genomic instabil-
ity, and the loss in chromatin structure are three of
the characteristics associated with both aging and
multifactorial or complex diseases [5, 80]. These
alterations are intrinsically linked to changes in the
epigenome [81, 82] and may be altered by environ-
mental factors [24]. There is evidence that shows
5-mC change over time. Consequently, changes in
methylation patterns might be linked to the aging
process; these changes are also associated with a
decrease in organ function, memory loss, bone den-
sity, and other health problems [83]. Normally, a
global decline in DNA methylation is the predom-
inant event in aging. For instance, in the senescent
cells of mice and humans, global hypomethylation is
produced, in comparison with the young cells [2].
However, age-related reduction in global 5-mC
levels does not affect repetitive DNA equally indi-
cating that individual sites, especially CpG islands,
become hypermethylated during aging. Furthermore,
in humans and mice, the CpG islands are in close
proximity to the promoters, which are typically
hypermethylated with age. It is interesting to note
that genes affected or modulated by these changes
are those encoding proteins related to differen-
tiation, development, inflammation, apoptosis, or
senescence, among others, are related to the neurode-
generative process.
Regarding the chromatin remodeling, and specifi-
cally the acetylation process, an increase in the global
acetylation patterns of histones H3 and H4 during
aging has been reported [84]. Likewise, the deregu-
lation of cellular autophagy, one of the characteristic
signs of aging, is associated with an increase in the
acetylation of histone H3 and changes in methyltrans-
ferase G9a activation [85].
Alterations in global methylation of histones H3
and H4 levels have been described during aging and
neurodegeneration [86–88]. These changes are also
produced in response to negative environmental mod-
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ifications that produce stress and anxiety [89] and
cellular damage [88]. In addition, TET1 and TET2 are
associated with aging and neurodegeneration [80].
In this regard, it is noteworthy that modifications
in gene expression of epigenetic enzymes, such as
the underexpression of DNMT 1 and 3A, as well as
of HMTs, GLP, and G9a, in differentiated neurons
cause alterations in memory and learning [90–92].
Of note, reduced expression of HDACs in both
HDAC2 and HDAC3 facilitates learning and mem-
ory formation, in turn increasing the number of
dendrites and synapses [93, 94]. Finally, the asso-
ciation between neuronal activity generated in each
psychological condition ranging from healthy, stress
disorder, addiction, and depression to neurodegener-
ative disorders such as AD is capable of modifying
the levels of 5-mC and 5-hmC, as well as histone
marks, and memory and learning are supported by
epigenetic modifications [95–99].
Furthermore, a specific demethylation of H4K
20me and H3K36me3, among others, and an increase
in positions H3K27me3, H3K79me, and H4K20me3
occur with age [89, 100, 101]. Additional evidence
is the alteration in protein levels of EZH2, a methyl-
transferase responsible for methylation at the H3K27
site, which is decreased in senescent cells [102].
Moreover, changes in the expression of class I
HDACs enzymes, such as HDAC1 and HDAC2,
leading to impairment in spatial and in contextual
memory, have been described [103–105]. In addition,
the involvement of class III HDACs, such as SIRT1,
SIRT2, and SIRT6, has been described in memory
formation and neurodegenerative processes [10, 106,
107]. Different studies have shown that SIRT1 has
a protective effect against AD [108] since it can
prevent the formation of A peptides deacetylating
RARb (Retinoic Acid Receptor beta) and activating
alpha-secretase ADAM10 [109]. SIRT1 deacetylates
tau and leads to its degradation, and in turn prevent-
ing its accumulation [110]. Otherwise, the epigenetic
marker H4K16ac, a substrate of deacetylase enzyme
SIRT2, increases during aging. Similarly, it has been
observed that SIRT6 deficiency affects longevity
and causes premature aging [111]. Finally, the inhi-
bition of other HDACs, such as class I HDACs
[103], improves cognitive impairment in aged mice
by increasing the acetylation of H4K12 [112, 113]
opening new avenues of AD therapies [114]. The lit-
erature reveals that at least 70% of known miRNAs
are expressed in the brain [115]. A correlation has
been demonstrated between changes in the expres-
sion of genes coding for miRNAs during aging and
disease and is also associated with changes in life
expectancy [116]. Furthermore, the underexpression
of various miRNAs inhibits senescence, and the over-
expression of some miRNAs promote it, appearing
to be one of the causes of senescence [117] as well
as increased global expression of miRNAs during
aging [118]. Interestingly, the location of the miR-
NAs within the cells, and specifically in the neuron, is
a specific feature of each miRNA. Different miRNAs
can be found in the synaptic region (e.g., miR-7), in
the neuronal axon (e.g., miR-16), or in the dendrites
(e.g., miR-26). It is well known that the cortex and
hippocampus are two brain regions that are especially
rich in miRNAs expression, also being the main cere-
bral areas involved in learning and memory processes
and neuronal plasticity [119].
Different microarrays studies indicate a general
increase in pro-oxidant and inflammatory genes in the
brain of aged rodents in comparison with adults and
implication for miRNAs has been described [120].
Moreover, cellular response to OS, an inducer of
genomic instability, induces the expression of miR-
NAs that in turn, reduce protein levels involved in
DNA repair and in genes related to oxidative phos-
phorylation leading to an increase in ROS. Therefore,
mitochondrial dysfunction suffers a loss of antiox-
idant capacity [121], the same one involved in the
aging process [122].
Some of the miRNAs implicated in the regulation
of inflammation are miR-124 and miR-29. miR-124
is expressed at higher levels in the brain more than in
the periphery, and some studies suggest a reduction
on this miRNA in the aged brain, although this decline
has only been observed in a small subpopulation of
microglia [123, 124]. miR-29 has been found at higher
levels within CNS microglia. One of the most impor-
tant changes in the brain of AD patients is upregula-
tion of the expression of the beta-secretase BACE1
[125]. It has been shown that miR-29 strongly inhibits
BACE1 in vitro and is markedly downregulated in
sporadic AD patients. Surprisingly, the opposite has
been found for non-pathological aging [120].
As mentioned previously, aging is the main risk
factor for developing neurodegeneration, and it has
become clear that in AD, many mechanisms are
involved that are also implicated in aging, interacting
in a complex way. The potential reversibility of
epigenetic changes that occur as a result of aging
offers interesting opportunities to alter the path of
age-related diseases. The following table listed some
epigenetic modifications occurring in aging and AD
(Table 3).
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Table 3
Epigenetic modifications during aging and AD
Observation Tissue or sample Reference
Hypomethylation of the APP protein promoter Human brain [126]
Hypomethylation of the promoter of ribosomal genes with aging Human stem cells [91]
Reduction in DNA methylation Human prefrontal cortex [127]
Difference in DNA methylation in discordant twins for AD Human temporal cortex [128]
Influence of steroids and aging on the methylation of the APP promoter Mouse brain [129]
Response to the metabolic stimulus of the PSEN1 gene regulated by DNA methylation Mouse brain [130]
Hypomethylation of proinflammatory genes: iNOS, IL-1, and TNF Human cortex [131]
Increased phosphorylation of histone H3 Hippocampal neurons [132]
Increased acetylation of histone H3 and H4 Mouse neurons [133]
Modification of the expression of chromatin regulatory enzymes Mouse brain [84]
Dysregulation of several miRNAs, overall increase in patients with AD Mouse brain [134]
SAMP8 MOUSE MODEL
The AD experimental models most widely used
at present are transgenic mice based on familial
AD mutations causing early-onset and severe AD
pathology [135, 136]. Therefore, AD transgenic mice
develop amyloid and/or tau pathology earlier than
cerebral age-related changes, while the age is the
main risk factor in the sporadic AD. To emulate
known AD risk factors, such as abnormal choles-
terol and insulin metabolism, some developed mice
models overexpress transgenes of APOE ε4 and
leptin, among others [137]. At present, there is
a reappraisal of the validity of naturally occur-
ring models by using aged animal species, such as
fruit flies, rabbits, dogs, and the guinea pig rela-
tive, Octodon degu, which reproduce physiological
changes appearing in sporadic AD [138]. An also
widely used rodent model, faithful of these sporadic
cases is the Senescence-Accelerated Prone Mouse 8
(SAMP8). This mouse-inbred strain provides inter-
esting and advantageous non-transgenic mice models
for research in AD [139, 140].
SAMP8 was established through phenotypic selec-
tion from a common genetic pool of AKR/J mice
strain and exhibits age-related deterioration in learn-
ing and memory abilities compared with the control
strain, Senescence-Accelerated Resistant Mouse 1
(SAMR1), established from the same AKR/J strain
[139]. Among a variety of age-related pathologic
phenotypes shown by SAMP inbred strains, SAMP8
develops early AD-like pathology [140].
SAMP8 mice have been proposed as a model for
studying the triggering and development of mild cog-
nitive impairment, early neurodegenerative AD-like
changes, and the progression of AD pathogenesis
[141]. It is assumed that the abnormality in senes-
cence and memory function observed in SAMP8 mice
depends on several factors, including morphologi-
cal, neurochemical, and neuropathological changes
[142]. Moreover, it is feasible that differences among
SAM strains could be explained on the basis of epi-
genetics, specifically in alterations that give rise to
changes in chromatin status [143].
SAMP8: Evidence as a sporadic Alzheimer’s
disease model
SAMP8 mice exhibit an accelerated aging phe-
notype with external signs of hair loss and lack
of hair glossiness, periophthalmic lesions, increased
lordokyphosis, and reduced physical activity [144,
145]. The sensorimotor performance of SAMP8 mice
also deteriorated with advancing age at a higher
pace than in SAMR1 mice [146]. Other senescence
traits include hearing impairment, deficits of immune
response, and lifespan shorter than that of control
SAMR1 mice [144]; namely, median life expectancy
was around 10 months for SAMP8 and 17 months
for SAMR1 [147, 148]. At the CNS level, SAMP8
demonstrate deficits in learning and memory and
emotional disorders. It is interesting to point out
that among the diverse SAMP strains of acceler-
ated senescence, only SAMP8 and SAMP10 showed
learning and memory defects [144]. Therefore, the
cognitive impairment of these strains might be related
to a few recessive genes among the many genes
controlling aging of the brain [149]. Furthermore,
underlying mechanisms are different for both strains,
as SAMP8 mice show AD-related traits, whereas
SAMP10 cognitive impairment is related to brain
atrophy [150]. Similarly, in humans, old age is a risk
factor for AD, but it does not unavoidably lead to the
disease in centenarians or, in the case of dementia, it
might not progress to AD. Therefore, only SAMP8
mice seems to be accelerated senescence after nor-
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mal development, but no other senescent strains show
progression into AD-like dementia.
Learning and memory impairment of SAMP8 was
first demonstrated in passive avoidance task, where
mild deficits were already evident at 2 months of
age and increased with advancing age [151]. These
authors demonstrated only minor impairments in the
Morris Water Maze (MWM) test at early age. A
number of successive studies confirmed the defec-
tive cognitive capacities of SAMP8 mice in a variety
of experimental tasks including MWM, radial arm
mazes, T/Y-maze, and passive avoidance and active
avoidance were clearly established at 8–12 months
of age [141, 152, 153]. However, current experimen-
tal interests rely on the analysis of early pathogenic
mechanisms of age-related neurodegeneration. In AD
dementia, the pathological brain processes are known
to develop for decades before cognitive impairment
can be detected clinically. Therefore, there are clini-
cal interests in moving to the phases of the preclinical
AD and early mild cognitive impairment for new clin-
ical trials against AD [154, 155]. Recent studies with
SAMP8 mice established the presence of cognitive
impairment in these mice compared to SAMR1 mice
at the age of 4–6 months in instrumental condition-
ing (passive avoidance and active avoidance), spatial
learning and memory (MWM, radial maze, and object
location test), and recognition memory with novel
object recognition test (NORT) [156–161].
Therefore, cognitive deficits in SAMP8 mice have
been characterized in a range of validated tests and
there is an agreement on the early and progressive
cognitively impaired responses of these mice [161,
162]. There were reported inconsistencies only in the
T-maze test [164, 165]. One of the best-characterized
responses is that of spatial learning and memory
in MWM. SAMP8 mice demonstrated a deterio-
rated and progressively impaired response in this
hippocampus-dependent task [146]. Indeed, the hip-
pocampus, a brain area that is highly sensitive to
AD, is severely affected by pathological alterations
in these mice. Furthermore, age-related behavioral
and cognitive alterations occurring in the SAMP8
are evident at 4 months in comparison with SAMR1
[165].
Regarding emotional disorders, SAMP8 exhib-
ited reduced anxiety-like behavior in the Plus Maze
Test (PMT), lower neophobia, and lower emotion-
ality and higher hyperactivity in the Open Field Test
(OFT) than SAMR1 mice [146, 160, 163, 166]. These
alterations of non-cognitive behavior were signif-
icant in 4-month-old SAMP8 and increased with
advancing age. Furthermore, other authors described
an enhancement of depression-like behavior in the
Forced Swim Test [161, 167] and a decrease of social
interaction [168]. Thus, SAMP8 mice show alter-
ations of non-cognitive behavior that do not generally
model the behavioral and psychological symptoms
of dementia (BPSD) associated with AD. BPSD
behaviors are mainly driven by AD pathology in the
cortical and basal ganglia areas, where pathology in
the SAMP8 mice might be less severe than in the
several strains of AD transgenic mice that reproduce
these typical neuropathological changes of AD [169].
The analysis of functional alterations underly-
ing the cognitive impairment of SAMP8 mice
revealed deficiencies in the mechanism of long-term
potentiation (LTP). LTP is based on long-term synap-
tic plasticity and memory formation [170]. LTP
recordings in vivo [158] or in hippocampal slices
[171–173] showed a correlation between deficits in
synaptic circuitry responses and the cognitive impair-
ment of these mice. The ratio of the electrophysio-
logical recordings of the paired-pulse stimulations,
which is on the basis of short-term synaptic plastic-
ity, also demonstrated deficiencies in SAMP8 mice in
vivo [158] and in hippocampal slices [173]. Reduc-
tion of synaptic markers, such as PSD95 and synap-
tophysin [174, 175], corroborated the hippocampus
plasticity deficiencies of SAMP8 mice. Furthermore,
reduced levels of glial cell line-derived neurotrophic
factor (GDNF) in the hippocampus of SAMP8 mice
were demonstrated transiently at an early age of
2–5 months compared to SAMR1 mice hippocampus
[176]. GDNF has been reported as highly neuropro-
tective against cognitive loss in a mouse model of AD
[177]. Another neurotrophic factor, the BDNF, was
also reported reduced in the SAMP8 mice hippocam-
pus [174, 178, 179]. Indeed, the reduction of BDNF
was concomitant to the decrease of the activation
of associated signaling factors Calcium-calModulin-
dependent Kinase II (CaMKII) and CREB [171]. The
reduced activation of the synaptic plasticity pathway
CaMKII-CREB-BDNF in SAMP8 may be derived
from a dysfunction of the NMDA receptor in these
mice [171]. An age-related loss of cholesterol in the
brain was proposed as the cause of the reduction
of this pathway [180]. Indeed, a diet supplemented
with plant sterols prevented the LTP reduction and
cognitive impairment shown by SAMP8 mice [172].
Reduced levels of BDNF and of phosphorylated
CaMKII in the hippocampus and in the cortex of AD
patients are suggested to contribute to the atrophy
and memory impairment in the disease [181, 182].
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Additionally, there is a derangement of cholesterol
metabolism in the AD brain [183].
SAMP8 mice showed higher levels of A peptides
and neurotoxic A oligomers than SAMR1 mice, as
demonstrated by ELISA and western blot techniques,
respectively [174]. This increase would be caused by
an abnormally elevated synthesis of the amyloid-
protein precursor (APP) [184, 185]. Strikingly, an
increase in the transcription of A(A4)PP gene was
detected as early as 2 months of age [184]. Concur-
rently, increased transcription of Bace1 and decreased
transcription of Adam10 would favor the amyloido-
genic processing pathway of APP [184]. A decrease
of the A metabolizing enzyme Insulin-degrading
enzyme (Ide) reported at 6 months of age might
also contribute to amyloid pathology in SAMP8 mice
[174]. Furthermore, age-related increase in prese-
nilin 1 in SAMP8 mice, but not in control strain
SAMR1, might also contribute to the imbalance in the
APP processing [186]. A diminution of A clear-
ance derived from disturbances in the blood-brain
barrier [187] is another significant factor leading to
amyloid pathology in these mice. The relevance of
A neurotoxicity in the SAMP8 phenotype was cor-
roborated by the protection against cognitive loss
afforded by the peripheral administration of an anti-
sense oligonucleotide against the A region of APP
[188] or an antibody against A42 [184]. It is known
that the sequence of murine A peptide differs in
three amino acid residues from human sequence,
this diminishing the capacity to produce amyloid
deposits except in the case of murine APP-bearing
mutations of human familial AD [189]. However, sev-
eral laboratories have documented the presence of
APP or A immunoreactive granular structures in
the SAMP8 brain, although devoid of the -pleated
sheet of human fibrillary A in AD plaques [190].
Clustered granules devoid of A and containing gly-
coside components were also identified early in the
SAMP8 hippocampus; these attributed to senescence
processes [191, 192]. Therefore, amyloid pathology
is well established in SAMP8 mice, although the
chemical characteristics of murine A do not allow
for its deposition in amyloid plaques. In the human
disease, A, both by increased accumulation in tar-
get brain areas and by the decreased presence in CSF,
is the earliest biomarker known for being detected in
preclinical phases of AD [193]. Similarly, the accu-
mulation of A in SAMP8 brain comprises an early
event in its progression to an AD-like phenotype.
Pathological accumulations of hyperphosphory-
lated tau (p-tau) were detected in the hippocampus
and cortex areas of SAMP8 mice. Analysis of AD-
related tau phosphorylation sites revealed increases
of p-tau in SAMP8 mice compared to SAMR1
mice aged between 3 and 9 months [174, 178, 184,
194–196]. Tau pathology is induced by the increased
activity of specific kinases, as supported by the
reported increased levels of activation of the kinases
Cdk5 [194–196], GSK3 Tyr216 [178], and JNK1
[174]. It is not known whether tau pathology pro-
gresses after amyloid accumulation or whether both
are parallel derangements in the SAMP8 mouse brain.
However, peripheral administration of an antisense
oligonucleotide directed at GSK3 Tyr216 improved
learning and memory in SAMP8 [197]. In any case,
the SAMP8 mice model spontaneously reproduces
both pathologies, similarly to most sporadic AD
cases. Contrariwise, AD transgenic mice might bear
familial tauopathy genes in addition to the familial
AD genes to exhibit significant tau pathology.
OS is a harmful imbalance of redox homeostasis
common to both brain aging and AD [198]. Changes
in OS including a decrease of antioxidant defense
enzymes, an increase of markers of oxidative damage,
and an increase of mitochondrial DNA deletions were
reported in the brain tissue of SAMP8 mice as early
as 2 months of age [199–201]. Signs of OS increased
along early and advanced age in SAMP8 mice com-
pared to SAMR1 mice [195, 202–204]. Oxidative
alterations were also present in peripheral tissues at
a range of age [200, 205–207]. OS might be induced
or worsened by mitochondrial alterations. Indeed,
brain mitochondrial respiration was dysfunctional at
2 months of age, demonstrating lower activity of com-
plex III [201–207]. Mitochondrial dysfunction plus
either increased generation of ROS or lower antiox-
idant defense was demonstrated in both neurons and
astrocytes cultured from SAMP8 embryonic brain tis-
sue [208–210]. SAMP8 liver mitochondria were also
dysfunctional but at later age of 6–12 months [203,
211–213]. The activities of A are numerous and yet
to be fully elucidated. However, it is well accepted
that the imbalanced in production and degradation of
A produces the neurodegeneration of AD and pro-
voking physiological effect in the brain [214, 215].
Likewise, the increased burden of A in the SAMP8
brain might contribute to earlier mitochondrial dys-
function and this impairment might be worsened by
the presence of p-tau in the SAMP8 brain [216]. Fur-
thermore, in vivo and in vitro studies support that
A generates free radicals, inducing protein oxida-
tion, lipid peroxidation, and DNA damage [217–221].
Accordingly, the treatment of 12-month-old SAMP8
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with antisense oligonucleotide directed against the
A region of APP decreased the levels of both A
and oxidative markers [222], improving cognition.
Although the interaction among A, OS, and AD
pathology is not well understood, a vicious cycle is
proposed in which alterations induced by OS would
increase accumulation of A and the subsequent AD
pathology, the latter in turn increasing mitochondrial
dysfunction and OS [223]. Despite the weight of OS
in AD, antioxidant therapies were demonstrated inef-
fective in clinical trials [224]. Therefore, the SAMP8
model with spontaneous OS, mitochondrial dysfunc-
tion, and A and p-tau accumulation in the brain
makes a useful model defining the mechanisms of free
radicals and mitochondrial dysfunction in AD [162].
Neuroinflammation is another age-related pro-
cess that, together with OS, paves the way for the
development of neurodegenerative diseases. Inflam-
matory signaling might contribute to AD triggering
and progression [225, 226]. Phenotypical traits of
inflammaging with higher expression of inflamma-
tory mediator molecules were found in the SAMP8
hippocampus at an early age of 2 months [24]. There
was also an increased response to acute inflamma-
tory injuries at 3 months of age in SAMP8 compared
to SAMR1, as detected by the levels of circulating
proinflammatory cytokines [227]. Inflammation was
also detected in peripheral tissues such as liver [228].
Inflammatory markers were generally maintained at
elevated levels with increasing age in the SAMP8
brain in comparison with SAMR1 [24, 229, 230].
Chronic inflammation in the SAMP8 hippocampus
was aggravated by deficiencies in the mechanisms of
resolution of inflammation [231]. Therefore, SAMP8
mice could not counteract inflammaging, and this
might contribute to the development of its sporadic
AD-like phenotype. At the cellular level, reactive
astrocytosis was shown in the SAMP8 hippocampus
[24, 179]. In this respect, astrogliosis measured the
GFAP marker that was present at 2 months of age
in SAMP8 mice, and maintained in old age [232],
thus confirming the onset of neuroinflammation at
early age. A decrease of the inflammatory regula-
tor Rcor2 might mediate the inflamed phenotype
of SAMP8 astrocytes [227]. Age-related stress-
mediated activation of transcription factor NF-k was
another proposed molecular mechanism of patholog-
ical inflammation in SAMP8 [228, 233]. Although
diverse transgenic mice models of AD reproduce OS
markers, neuroinflammation and gliosis appear only
at the advanced age and is associated with a heavy
load of amyloid plaques [139, 140]. Neuron loss,
one of the hallmarks of AD, has been described in
the hippocampus of 8-month-old SAMP8, paralleling
an elevated stage of neurodegeneration [234]. Hip-
pocampus, the most affected brain area in SAMP8, is
an essential area for memory function and its func-
tional circuitry is very sensitive to AD pathology.
In addition to the AD-like neuropathology discussed
earlier, SAMP8 showed a progressive impairment
of cholinergic neurotransmission, as reported at 8
months of age in the hippocampus and cerebral cor-
tex [165], similarly to the main neurotransmission
defects observed in AD patients [235].
Proteomics, metabolomics, genomics, and tran-
scriptomics studies of SAMP8 brain tissue confirmed
the presence of AD-like pathological traits in the
brain of SAMP8 mice [236–240]. As a whole, the
specific senescent-associated alterations in SAMP8
brain comprise a scenario for the development and
progression of an AD-like phenotype including the
main AD traits of neuropathology and memory loss.
Therefore, SAMP8 is an excellent mice model to
analyze mechanisms and therapies for sporadic AD,
whose main risk factor is advancing age.
Epigenetics of aging and sporadic Alzheimer’s
disease-like phenotype in SAMP8
As mentioned previously, the SAMP8 model has
been widely used to study senescence in all systems
and from different points of view, including cerebral
senescence [139, 144]. SAMP strains were gener-
ated by the phenotypic selection of crosses between
siblings but, as mentioned extensively in the intro-
duction, the causes of accelerated senescence have
not been established.
The participation of OS, the evolution of neu-
roinflammation, and its correlation with changes in
behavior and cognitive impairment, including the
alterations in gene expression and protein aberra-
tions associated with aging and neurodegenerative
processes, are SAMP8 strain characteristics well
reported. The fact that the SAMP8 mouse is a spon-
taneous animal model and not transgenic mice model
of AD suggests that the underlying orchestra mech-
anisms must be linked to epigenetics. In this respect,
several results corroborate the existence of epigenetic
modifications related to aging and neurodegenera-
tion in SAMP8 [25, 227]. It is well known that
epigenetic machinery is highly modulated by envi-
ronmental factors such as diet or exercise. Moreover,
several studies in SAMP8 demonstrated that exercise
[25], EE [233], or resveratrol-enriched diet [148, 241]
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induced changes in the expression of Sirt1, one of
the class III HDACs related to epigenetic marks.
Therefore, all this evidence indicated that SAMP8
strain is affected by epigenetic changes in reference
to SAMR1 that favors mice to accelerate senescence
and present AD-like processes.
For instance, EE increased global 5-mC levels in
younger SAMP8 (2 months old), accompanied by
reduced 5-hmC levels. Changes in gene expression of
Dnmt3b, Hdac1/2, Sirt2, and Sirt6 were also found in
SAMP8 under EE. Moreover, increased acetylation
in H3 and H4 was found in the same experimental
conditions [233].
A recent study showed a reduction in the gene
expression of the chromatin regulator Rcor2 in
SAMP8, which was found in reference to SAMR1.
Reduced levels of Rcor2 complex increases inflam-
mation in the SAMP8 strain by suppression of gene
repression, such as Il-6, Ccl2, Ccl3, Cxcl5, Cxcl10,
and Mpa2l [227].
The level of seven histone methylation sites, most
located on histone H3 (H3K24, H3K27, H3K36,
H3K79, H3R128, H4K20 and H2AR89), were found
significantly decreased in the SAMP8 brain with
respect to SAMR1 [242], providing evidence that
posttranslational modification in SAMP8 is linked to
senescence process.
It has been published that expression of Dnmt3b
was increased in SAMP8 after injection of ery-
thropoietin improving spatial learning and memory,
indicating that the methylation state of DNA is neces-
sary for learning and memory, including the memory
formation [243]. Epigenetic mechanisms underlying
cognitive impairment by accelerated aging in SAMP8
were also found in an AD mice model, as 5xFAD,
where A is a key factor in cognitive impairment and
neurodegeneration [233, 244].
It has been demonstrated that miRNAs also play an
important role in the SAMP8 model [25], corroborat-
ing what has already been described concerning the
role of miRNAs, both in development and in aging
[245]. The first study demonstrated that miR-16 is
underexpressed in the SAMP8 strain and that miR-
16 reduces the protein levels of APP [246]. Other
authors demonstrated higher expression of miR-139
in the hippocampus of aged SAMP8 than in SAMR1.
When miR-139 is overexpressed in SAMP8, the
hippocampus-dependent learning and memory for-
mation by modulating cannabinoid receptor type 2
(CB2) is impaired, whereas downregulation of miR-
139 leads to an improvement in learning and memory
[247].
Another study showed the abnormal expression of
genes (nodes) of certain biological networks related
to the AD patients were regulated by miRNAs such
as miR-20a; -17, -34a; -155; -18a; -22; -26a; -101;
-106b, and -125b and were found changed in SAMP8
in comparison with SAMR1 [248]. Furthermore,
there are significant alterations in the expression of
various genes of HDACs enzymes, such as Sirt1,
Hdac5, and Hdac6, and also of the global levels of
acetylation of histones H3 and H4 and of various
miRNAs in the hippocampus in the SAMP8 female
at 8 months of age, which partially revert with an
intervention of voluntary exercise [25]. Finally, the
use of the HDAC inhibitor, trichostatin, allowed the
reversal of the senescent phenotype and DNA dam-
age by increasing the levels of histone acetylation,
and increasing the proliferation of exhausted NSC of
SAMP8 in vitro [143].
In addition, a significant reduction in the expres-
sion of the miR-9 family in the SAMP8 strain
compared to the age-matched SAMR1 control was
found; this miR-9 regulated in silico the genes PSEN1,
SCN2B, MAP3K3, and BACE1 [249]. This would
explain in part the cognitive impairment and patho-
logical process of SAMP8 mice model, confirming
its relationship with aging and AD.
Correlating the described modifications with cel-
lular processes mentioned comprises a task that must
be carried out in order to further demonstrate that
miRNAs can control protein levels and in turn influ-
ence brain function and the cognitive abilities in
SAMP8. The involvement of epigenetic modulation
in the aging process, the neurodegeneration, and the
central role of the gene regulation of miRNAs, could
explain in part that the senescent phenotype found in
the SAMP8 strain is an issue to be developed.
In sum, published results demonstrate the partic-
ipation of epigenetic modulation in the aging and
neurodegenerative processes, and the central role of
gene regulation that miRNAs possess, explain in part
the senescent phenotype that characterizes SAMP8.
CONCLUSIONS
Accumulating evidence proves that neurological
disorders are closely related to the age and that neu-
rodegenerative diseases are not an exception. The
aging process, both in physiological and patholog-
ical conditions, as occurs in AD, can be driven
by epigenetic forces. Epigenetic changes are influ-
enced by lifestyle (diet, exercise, smoking, etc.), by
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external environment factors (drugs, chemicals, etc.),
and also by genetic inheritance. In the brain, any
small change might induce disturbances that will
lead to emotional imbalances, cognitive impairment,
and neurodegeneration. The SAMP8 mice model has
revealed cognitive and behavioral disturbances that
occur at early age and that worsen with senescence.
The accelerated senescence and, in particular, the
cognitive impairment present in this murine model
together with the epigenetic marker changes that are
reviewed here, suggest this strain as a feasible option
to reveal new targets and to study novel drugs to face
harmful aging processes.
ACKNOWLEDGMENTS
This study was supported by Spanish MINECO
(SAF2016-77703, CSD2010-00045), and the Euro-
pean Regional Development Funds, and 2017-SGR-
106 and the CERCA Programme from the Generalitat
de Catalunya.
Authors’ disclosures available online (https://
www.j-alz.com/manuscript-disclosures/17-0664r5).
REFERENCES
[1] Alzheimer’s Association (2016) Alzheimer’s disease facts
and figures. Alzheimers Dement 12, 459-509.
[2] Brunet A, Berger L (2014) Epigenetics of aging and
aging-related disease. J Gerontol A Biol Sci Med Sci 69,
S17-S20.
[3] Delgado-Morales R, Agı́s-Balboa RC, Esteller M,
Berdasco M (2017) Epigenetic mechanisms during ageing
and neurogenesis as novel therapeutic avenues in human
brain disorders. Clin Epigenetics 9, 67.
[4] Mastroeni D, Grover A, Rogers J (2011) Epigenetics
mechanisms in Alzheimer’s disease. Neurobiol Aging 32,
1161-1180.
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[125] Hébert SS, Horré K, Nicolai L, Papadopoulou AS, Man-
demakers W, Silahtaroglu AN Kauppinen S, Delacourte
A, Strooper BD (2008) Loss of microRNA cluster miR-
29a/b-1 in sporadic Alzheimer’s disease correlates with
increased BACE1/beta-secretase expression. Proc Nat
Acad Sci U S A 105, 6415-6416.
[126] Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Genda
Y, Ukitsu M (1999) Reduction with age in methylcytosine
in the promoter region –224 approximately –101 of the
amyloid precursor protein gene in autopsy human cortex.
Brain Res Mol Brain Res 70, 288-292.
[127] Xu X (2015) DNA methylation and cognitive aging. Onco-
target 6, 13922-13932.
[128] Castellani CA, Laufer BI, Melka MG, Diehl EJ, O’Reilly
RL, Singh SM (2015) DNA methylation differences in
monozygotic twin pairs discordant for schizophrenia iden-
tifies psychosis related genes and networks. BMC Med
Genomics 8, 17.
[129] Maloney B, Sambamurti K, Zawia N, Lahiri DK (2012)
Applying epigenetics to Alzheimer’s disease via the latent
early-life associated regulation (LEARn) model. Curr
Alzheimer Res 9, 589-599.
[130] Fuso A, Nicolia V, Pasqualato A, Fiorenza MT, Caval-
laro RA, Scarpa S (2011) Changes in Presenilin 1 gene
methylation pattern in diet-induced B vitamin deficiency.
Neurobiol Aging 32, 187-199.
[131] Bayarsaihan D (2011) Epigenetic mechanisms in inflam-
mation. J Dent Res Jan 90, 9-17.
[132] Sawicka A, Seiser C (2012) Histone H3 phosphorylation –
a versatile chromatin modification for different occasions.
Biochimie 94, 2193-2201.
[133] Mori T, Wakabayashi T, Ogawa H, Hirahara Y, Koike T,
Yamada H (2013) Increased histone H3 phosphorylation
in neurons in specific brain structures after induction of
status epilepticus in mice. PLoS One 8, e77710.
[134] Hu YB, Li CB, Song N, Zou Y, Chen SD, Ren RJ, Wang
G (2016) Diagnostic value of microRNA for Alzheimer’s
disease: A systemic review and meta-analysis. Front Aging
Neurosci 8, 13.
[135] Drummond E, Wisniewski T (2017) Alzheimer’s disease:
Experimental models and reality. Acta Neuropathol 133,
155-175.
[136] Esquerda-Canals G, Montoliu-Gaya L, Güell-Bosch J, Vil-
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[158] López-Ramos JC, Jurado-Parras MT, Sanfeliu C, Acuña-
Castroviejo D, Delgado-Garcı́a JM (2012) Learning
capabilities and CA1-prefrontal synaptic plasticity in a
mice model of accelerated senescence. Neurobiol Aging
33, 13-26.
[159] Zhang X, Li G, Guo L, Nie K, Jia Y, Zhao L, Yu J (2013)
Age-related alteration in cerebral blood flow and energy
failure is correlated with cognitive impairment in the
senescence-accelerated prone mouse strain 8 (SAMP8).
Neurol Sci 34, 1917-1924.
[160] Sawano E, Negishi T, Aoki T, Murakami M, Tashiro T
(2013) Alterations in local thyroid hormone signaling
in the hippocampus of the SAMP8 mouse at younger
ages: Association with delayed myelination and behav-
ioral abnormalities. J Neurosci Res 91, 382-392.
[161] Yanai S, Endo S (2016) Early onset of behavioral alter-
ations in senescence-accelerated mouse prone 8 (SAMP8).
Behav Brain Res 308, 187-195.
[162] Morley JE, Farr SA, Kumar VB, Armbrecht HJ (2012)
The SAMP8 mouse: A model to develop therapeutic inter-
ventions for Alzheimer’s disease. Curr Pharm Des 18,
1123-1130.
[163] Yagi H, Katoh S, Akiguchi I, Takeda T (1988) Age-related
deterioration of ability of acquisition in memory and learn-
ing in senescence accelerated mouse: SAM-P/8 as an
animal model of disturbances in recent memory. Brain
Res 474, 86-93.
[164] Spangler EL, Patel N, Speer D, Hyman M, Hengemihle
J, Markowska A, Ingram DK (2002) Passive avoidance
and complex maze learning in the senescence accelerated
mouse (SAM): Age and strain comparisons of SAM P8
and R1. J Gerontol A Biol Sci Med Sci 57, B61-B68.
[165] Wang F, Chen H, Sun X (2009) Age-related spatial cogni-
tive impairment is correlated with a decrease in ChAT in
the cerebral cortex, hippocampus and forebrain of SAMP8
mice. Neurosci Lett 454, 212-217.
[166] Miyamoto M, Kiyota Y, Nishiyama M, Nagaoka A
(1992) Senescence-accelerated mouse (SAM): Age-
related reduced anxiety-like behavior in the SAM-P/8
strain. Physiol Behav 51, 979-985.
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D, Verdaguer E, Jiménez A, Junyent F, Lau A, Camins
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